Evidence map›Paper›PMID 40814320›Full record

ArticleAnnals of pediatric cardiology

Everolimus therapy in an infant with Noonan syndrome with multiple lentigines.

Mani Ram Krishna, Usha Nandhini Sennaiyan

Abstract readCase Reports
In one paragraph

Article in Annals of pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mani Ram KrishnaDepartment of Pediatric Cardiology, Tiny Hearts Hospital, Thanjavur, Tamil Nadu, India.
Usha Nandhini SennaiyanDepartment of Pediatric Cardiology, Tiny Hearts Hospital, Thanjavur, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RASopathies are the most common underlying etiology in infants with hypertrophic cardiomyopathy. An improved understanding of the downstream molecular mechanisms of the disease has enabled us to target therapy for genetic abnormalities in human cancers with somatic mutations in the RASopathy genes. This therapy is now being extended to RASopathies, which are due to germline mutations in the same genes. We report an infant with Noonan syndrome with multiple lentigines who presented with symptomatic heart failure in infancy. Everolimus therapy over 1 year resulted in symptomatic improvement with no significant adverse clinical events.

Indexed as

LEOPARD syndromeprecision medicineRASopathy

Identifiers

PMID40814320
PMCPMC12348754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.